Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Advanced Chemotherapy Technologies Inc (AKA: ACT)
Profile last edited on: 8/31/2021      CAGE: 7TN07      UEI: CYKRUDNRVZ85

Business Identifier: Device to infuse chemotherapies into poorly vascularized tumors
Year Founded
2014
First Award
2017
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2301 Stonehenge Drive Suite 115
Raleigh, NC 27615
   (919) 368-0522
   info@advancedchemotech.com
   advancedchemotech.com
Location: Single
Congr. District: 02
County: Wake

Public Profile

Structured around developing breakthrough combination drug-device technologies to tackle cancers that are difficult to treat, Advanced Chemotherapy Technologies Inc (aka ACT) is a medical company having currently a particular focus on pancreatic cancer. The firm's lead product is the first-in-class to combine iontophoresis drug delivery with an implantable delivery system to target drug delivery with laser-like precision. Advanced Chemotherapy Technologies drug delivery technology was first developed at and licensed from the University of North Carolina at Chapel Hill in conjunction with UNC Lineberger Comprehensive Cancer Center.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$299,805
Phase II Dollars
$5,884,824
Total Awarded
$6,184,629

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 2 NIH $6,184,629
Project Title: Implantable Iontophoresis Chemotherapy Delivery Device for Direct Infusion of Gemcitabine Into Pancreatic Adenocarcinoma: Device Development and First-In-Human Clinical Trial

Key People / Management

  Anthony (Tony) Voiers -- Founder and CEO

  William Daunch -- CTO

  Francisco J De Ana Arbeloa

  Joseph M Desimone -- Executive Chairman and Co-Founder

  Jen Jen Yeh -- Founder

Company News

There are no news available.